Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRR1 | P24046 | 1/20 | 0.32 |
| ▸ | CHRNB2 | P17787 | 4/20 | 0.31 |
| ▸ | CHRNA3 | P32297 | 4/20 | 0.31 |
| ▸ | CHRNA4 | P43681 | 4/20 | 0.31 |
| ▸ | CHRNB3 | Q05901 | 4/20 | 0.31 |
| ▸ | CHRNA6 | Q15825 | 4/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19617869 | 1.00 | GABRR1 (0.32) | GABRR1CHRNB2CHRNA3CHRNA4CHRNB3 | |
| SCHEMBL19617268 | 1.00 | GABRR1 (0.32) | GABRR1CHRNB2CHRNA3CHRNA4CHRNB3 | |
| SCHEMBL4243520 | 1.00 | GABRR1 (0.32) | GABRR1CHRNB2CHRNA3CHRNA4CHRNB3 | |
| SCHEMBL4243523 | 1.00 | GABRR1 (0.32) | GABRR1CHRNB2CHRNA3CHRNA4CHRNB3 | |
| SCHEMBL4243525 | 1.00 | GABRR1 (0.32) | GABRR1CHRNB2CHRNA3CHRNA4CHRNB3 | |
| SCHEMBL505155 | 0.85 | FUCA1 (0.34) | — | |
| SCHEMBL19816446 | 0.83 | GABRR1 (0.39) | GABRR1 | |
| SCHEMBL3620778 | 0.83 | GABRR1 (0.39) | GABRR1 | |
| SCHEMBL3620776 | 0.83 | GABRR1 (0.39) | GABRR1 | |
| SCHEMBL4627762 | 0.83 | GABRR1 (0.39) | GABRR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024127350-A1 | 2,6,9-TRISUBSTITUTED PURINES | ASTRAZENECA AB (SE) | 2024-06-20 | — | — | WO | disclosed |
| WO-2023199091-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-10-19 | — | — | WO | disclosed |
| EP-3893879-A1 | PYRAZOLOPYRIDINE INHIBITORS OF C-JUN-N-TERMINAL KINASES AND USES THEREOF | Dana-Farber Cancer Institute, Inc. (US) | 2021-10-20 | — | — | EP | disclosed |
| EP-3508482-B1 | INHIBITORS OF FIBROBLAST GROWTH FACTOR RECEPTOR AND USE THEREOF | NANJING TRANSTHERA BIOSCIENCES CO LTD (CN) | 2020-12-16 | — | — | EP | disclosed |
| US-10744139-B2 | Inhibitors of fibroblast growth factor receptor and use thereof | NANJING TRANSTHERA BIOSCIENCES CO. LTD. (CN) | 2020-08-18 | — | — | US | disclosed |
| WO-2020123925-A1 | PYRAZOLOPYRIDINE INHIBITORS OF C-JUN-N-TERMINAL KINASES AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-06-18 | — | — | WO | disclosed |
| US-20190209564-A1 | INHIBITORS OF FIBROBLAST GROWTH FACTOR RECEPTOR AND USE THEREOF | NANJING TRANSTHERA BIOSCIENCES CO LTD (CN) | 2019-07-11 | — | — | US | disclosed |
| EP-3508482-A1 | INHIBITORS OF FIBROBLAST GROWTH FACTOR RECEPTOR AND USE THEREOF | Nanjing Transthera Biosciences Co. Ltd. (CN) | 2019-07-10 | — | — | EP | disclosed |
| EP-3458449-A1 | BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | Xenon Pharmaceuticals Inc. (CA) | 2019-03-27 | — | — | EP | disclosed |
| WO-2017201468-A1 | BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2017-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10744139-B2 | Inhibitors of fibroblast growth factor receptor and use thereof | FGFR1, FGFR2, FGFR3 | GABRR1 1584/4885CHRNB2 4703/4885CHRNA3 4737/4885 |
| US-20190209564-A1 | INHIBITORS OF FIBROBLAST GROWTH FACTOR RECEPTOR AND USE THEREOF | FGFR1, FGFR2, FGFR3 | GABRR1 1584/4885CHRNB2 4703/4885CHRNA3 4737/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.